Changes in the blood plasma lipidome associated with effective or poor response to atypical antipsychotic treatments in schizophrenia patients
Open accessPublished version of a preprint
Abstract
Atypical antipsychotics are widely used to manage schizophrenia symptoms. However, these drugs can induce deleterious side effects, such as MetS, which are associated with an increased cardiovascular risk to patients. Lipids play a central role in this context, and changes in lipid metabolism have been implicated in schizophrenia's pathobiology. Furthermore, recent evidence suggests that lipidome changes may be related to antipsychotic treatment response. The aim of this study was to evaluate the lipidome changes in blood plasma samples of schizophrenia patients before and after 6 weeks of treatment with either risperidone, olanzapine, or quetiapine. Liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis showed changes in the levels of ceramides (Cer), glycerophosphatidic acids (PA), glycerophosphocholines (PC), phosphatidylethanolamines (PE), phosphatidylinositols (PI), glycerophosphoglycerols (PG), and phosphatidylserines (PS) for all treatments. However, the treatment with risperidone also affected diacylglycerides (DG), ceramide 1-phosphates (CerP), triglycerides (TG), sphingomyelins (SM), and ceramide phosphoinositols (PI-Cer). Moreover, specific lipid profiles were observed that could be used to distinguish poor and good responders to the different antipsychotics. As such, further work in this area may lead to lipid-based biomarkers that could be used to improve the clinical management of schizophrenia patients.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Olanzapine mainly affects the PS, PC, glycerophosphatidic acid PA, and glycerophosphoglycerol PG lipid classes.
“Olanzapine mainly affected the PS, PC, glycerophosphatidic acid PA, and glycerophosphoglycerol PG lipid classes.”
From Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers (2024) · cites this paper as [141]
Risperidone affects DG, ceramide 1-phosphates, TG, SM, and ceramide phosphoinositols.
“Risperidone affected DG, ceramide 1-phosphates, TG, SM, and ceramide phosphoinositols.”
From Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers (2024) · cites this paper as [141]
Quetiapine affects the lipid profiles of patients to a smaller extent.
“Quetiapine affected the lipid profiles of patients to a smaller extent.”
From Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers (2024) · cites this paper as [141]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Owen, M. J., Sawa, A., & Mortensen, P. B. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01121-6 · Cited by 1,870 · see citing works
Mitchell, A. J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W., & Binder, M. D. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr148 · Cited by 1,087 · see citing works
Double-check: validation of diagnostic statistics for PLS-DA models in metabolomics studies
Szymańska, E., Saccenti, E., Smilde, A. K., & Westerhuis, J. A. (2011) · Metabolomics · doi:10.1007/s11306-011-0330-3 · Cited by 913 · see citing works
Rummel‐Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.012 · Cited by 679 · see citing works
Life expectancy and cardiovascular mortality in persons with schizophrenia
Laursen, T. M., Munk-Olsen, T., & Vestergaard, M. (2012) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32835035ca · Cited by 518 · see citing works
Horrobin, D. F. (1998) · Schizophrenia Research · doi:10.1016/s0920-9964(97)00151-5 · Cited by 456 · see citing works
Koro, C. E., Fedder, D. O., L'Italien, G. J., Weiss, S., Magder, L., Kreyenbuhl, J., Revicki, D., & Buchanan, R. (2002) · BMJ · doi:10.1136/bmj.325.7358.243 · Cited by 421 · see citing works
Multivariate paired data analysis: multilevel PLSDA versus OPLSDA
Westerhuis, J. A., van Velzen, E. J. J., Hoefsloot, H. C. J., & Smilde, A. K. (2009) · Metabolomics · doi:10.1007/s11306-009-0185-z · Cited by 419 · see citing works
A neuroscientist's guide to lipidomics
Piomelli, D., Astarita, G., & Rapaka, R. S. (2007) · Nature reviews. Neuroscience · doi:10.1038/nrn2233 · Cited by 380 · see citing works
Sarafian, M. H., Gaudin, M., Lewis, M. R., Martin, F., Holmes, E. C., Nicholson, J. K., & Dumas, M. (2014) · Analytical Chemistry · doi:10.1021/ac500317c · Cited by 303 · see citing works
Sterol regulatory element binding protein 1 couples mechanical cues and lipid metabolism
Bertolio, R., Napoletano, F., Mano, M., Maurer‐Stroh, S., Fantuz, M., Zannini, A., Bicciato, S., Sorrentino, G., & Sal, G. D. (2019) · Nature Communications · doi:10.1038/s41467-019-09152-7 · Cited by 296 · see citing works
Metabolomic Mapping of Atypical Antipsychotic Effects in Schizophrenia
Kaddurah-Daouk, R., McEvoy, J., Baillie, R. A., Lee, D., Yao, J. K., Doraiswamy, P. M., & Krishnan, K. R. R. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002000 · Cited by 262 · see citing works
Metabolism and functions of lipids in myelin
Schmitt, S., Cantuti‐Castelvetri, L., & Simons, M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.12.016 · Cited by 259 · see citing works
Metabolic profile of antipsychotic-naive individuals with non-affective psychosis
Fernández-Egea, E., Bernardo, M., Donner, T. W., Conget, I., Parellada, E., Justicia, A., Esmatjes, E., García‐Rizo, C., & Kirkpatrick, B. W. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.108.052605 · Cited by 242 · see citing works
Schwarz, E., Prabakaran, S., Whitfield, P. D., Major, H. J., Leweke, F. M., Koethe, D., McKenna, P. J., & Bahn, S. (2008) · Journal of Proteome Research · doi:10.1021/pr800188y · Cited by 222 · see citing works
Serum Leptin and Triglyceride Levels in Patients on Treatment With Atypical Antipsychotics
Atmaca, M., Kuloğlu, M., Tezcan, E., & Üstündağ, B. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0516 · Cited by 181 · see citing works
Weight gain and antipsychotics: a drug safety review
Musil, R., Obermeier, M., Russ, P., & Hamerle, M. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.974549 · Cited by 167 · see citing works
Multilevel data analysis of a crossover designed human nutritional intervention study
van Velzen, E. J. J., Westerhuis, J. A., van Duynhoven, J. P. M., van Dorsten, F. A., Hoefsloot, H. C. J., Jacobs, D. M., Smit, S., Draijer, R., Kroner, C. I., & Smilde, A. K. (2008) · Journal of Proteome Research · doi:10.1021/pr800145j · Cited by 161 · see citing works
Vestri, H. S., Maianu, L., Moellering, D. R., & Garvey, W. T. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301142 · Cited by 153 · see citing works
Misiak, B., Stańczykiewicz, B., Łaczmański, Ł., & Frydecka, D. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.03.031 · Cited by 151 · see citing works
Martins‐de‐Souza, D., Gattaz, W. F., Schmitt, A., Rewerts, C., Marangoni, S., Novello, J. C., Maccarrone, G., Turck, C. W., & Dias‐Neto, E. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0156-y · Cited by 146 · see citing works
Self-citationEngl, J., Rettenbacher, M., Fleischhacker, W. W., & Ebenbichler, C. F. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301366 · Cited by 139 · see citing works
Altered thalamic membrane phospholipids in schizophrenia: a postmortem study
Schmitt, A., Wilczek, K., Blennow, K., Maras, A., Jatzko, A., Petroianu, G. A., Braus, D. F., & Gattaz, W. F. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.03.019 · Cited by 134 · see citing works
McEvoy, J., Baillie, R. A., Zhu, H., Buckley, P., Keshavan, M. S., Nasrallah, H. A., Dougherty, G. G., Yao, J. K., & Kaddurah-Daouk, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068717 · Cited by 127 · see citing works
Evidence for disruption of sphingolipid metabolism in schizophrenia
Narayan, S., Head, S. R., Gilmartin, T. J., Dean, B., & Thomas, E. A. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21822 · Cited by 114 · see citing works
Raben, A., Marshe, V. S., Chintoh, A. F., Gorbovskaya, I., Müller, D. J., & Hahn, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00741 · Cited by 114 · see citing works
Hellard, S. L., Theisen, F., Haberhausen, M., Raeder, M. B., Fernø, J., Gebhardt, S., Hinney, A., Remschmidt, H., Krieg, J. C., Mehler‐Wex, C., et al. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002133 · Cited by 102 · see citing works
Tessier, C., Sweers, K., Frajerman, A., Bergaoui, H., Ferreri, F., Delva, C., Lapidus, N., Lamazière, A., Roiser, J. P., Hert, M. A. F. D., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.142 · Cited by 101 · see citing works
Procyshyn, R. M., Wasan, K. M., Thornton, A. E., Barr, A. M., Chen, E. Y. H., Pomarol‐Clotet, E., Stip, É., Williams, R. L., MacEwan, G. W., Birmingham, C. L., et al. (2007) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0733 · Cited by 96 · see citing works
Erythrocyte membrane phospholipids in psychotic patients
Keshavan, M. S., Mallinger, A. G., Pettegrew, J. W., & Dippold, C. S. (1993) · Psychiatry Research · doi:10.1016/0165-1781(93)90032-c · Cited by 95 · see citing works
Falkai, P., Malchow, B., Wetzestein, K., Nowastowski, V., Bernstein, H., Steiner, J. H., Schneider-Axmann, T., Kraus, T. F. J., Hasan, A., Bogerts, B., et al. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv157 · Cited by 89 · see citing works
Self-citationThe impact of mental illness on cardiac outcomes: A review for the cardiologist
Sowden, G. L., & Huffman, J. C. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.10.002 · Cited by 86 · see citing works
Studies on modulation of feeding behavior by atypical antipsychotics in female mice
Kaur, G., & Kulkarni, S. K. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00266-4 · Cited by 81 · see citing works
Quantification of endocannabinoids in postmortem brain of schizophrenic subjects
Muguruza, C., Lehtonen, M., Aaltonen, N., Morentín, B., Meana, J. J., & Callado, L. F. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.06.013 · Cited by 79 · see citing works
Risk of weight gain for specific antipsychotic drugs: a meta-analysis
Spertus, J. V., Horvitz-Lennon, M. V., Abing, H. K., & Normand, S. T. (2018) · Schizophrenia · doi:10.1038/s41537-018-0053-9 · Cited by 77 · see citing works
A clinical study of the association of antipsychotics with hyperlipidemia
de León, J., Susce, M. T., Johnson, M., Hardin, M., Pointer, L., Ruaño, G., Windemuth, A., & DÍAZ, F. J. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.01.015 · Cited by 76 · see citing works
Keshavan, M. S., Stanley, J. A., Montrose, D. M., Minshew, N. J., & Pettegrew, J. W. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001325 · Cited by 76 · see citing works
Hahn, M., Chintoh, A. F., Giacca, A., Xu, L., Lam, L., Mann, S. W., Fletcher, P. J., Guenette, M. D., Cohn, T. A., Wolever, T., et al. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.06.004 · Cited by 76 · see citing works
Khakimov, B., Poulsen, S. K., Savorani, F., Acar, E., Gürdeniz, G., Larsen, T. M., Astrup, A. V., Dragsted, L. O., & Engelsen, S. B. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00109 · Cited by 63 · see citing works
Sjögren, B., & Svenningsson, P. (2007) · Acta Physiologica · doi:10.1111/j.1365-201x.2007.01687.x · Cited by 59 · see citing works
Ghosh, S., Dyer, R., & Beasley, C. L. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.08.009 · Cited by 56 · see citing works
Profiling of Lipidomics Before and After Antipsychotic Treatment in First-Episode Psychosis
Leppik, L., Parksepp, M., Janno, S., Koido, K., Haring, L., Vasar, E., & Zilmer, M. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0971-6 · Cited by 55 · see citing works
Skin Ceramide Alterations in First-Episode Schizophrenia Indicate Abnormal Sphingolipid Metabolism
Smesny, S., Schmelzer, C. E. H., Hinder, A., Köhler, A., Schneider, C., Rudzok, M., Schmidt, U., Milleit, B., Milleit, C., Nenadić, I., et al. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs058 · Cited by 48 · see citing works
Steen, V. M., Skrede, S., Polushina, T. V., López, M., Andreassen, O. A., Fernø, J., & Hellard, S. L. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.07.011 · Cited by 47 · see citing works
Increases in triglyceride levels are associated with clinical response to clozapine treatment
Lally, J., Gallagher, A., Bainbridge, E. D., Avalos, G., Ahmed, M. R., & McDonald, C. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112472568 · Cited by 46 · see citing works
Weber‐Fahr, W., Englisch, S., Esser, A., Tunc‐Skarka, N., Meyer‐Lindenberg, A., Ende, G., & Zink, M. (2013) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2013.06.011 · Cited by 42 · see citing works
Phospholipid patterns of erythrocytes in schizophrenia: relationships to symptomatology
Ponizovsky, A. M., Modai, I., Nechamkin, Y., Barshtein, G., Ritsner, M., Yedgar, S., Lecht, S., & Bergelson, L. D. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00189-4 · Cited by 42 · see citing works
Knight, J. A., Smith, C., Toohey, N., Klein, M. T., & Teitler, M. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.052084 · Cited by 41 · see citing works
Effect of phosphatidylserine on memory in patients and rats with Alzheimer’s disease
Zhang, Y. Y., Yang, L., & Guo, L. (2015) · Genetics and Molecular Research · doi:10.4238/2015.august.10.13 · Cited by 40 · see citing works
Sato, H., Ito, C., Hiraoka, K., Tashiro, M., Shibuya, K., Funaki, Y., Yoshikawa, T., Iwata, R., Matsuoka, H., & Yanai, K. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4002-2 · Cited by 39 · see citing works
Lauressergues, E., Martin, F., Helleboid‐Chapman, A., Bouchaert, E., Cussac, D., Bordet, R., Hum, D. W., Luc, G., Majd, Z., Staels, B., et al. (2011) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-010-0597-3 · Cited by 38 · see citing works
Nasrallah, H. A., Newcomer, J. W., Risinger, R. C., Du, Y., Zummo, J., Bose, A., Stankovic, S., Silverman, B. L., & Ehrich, E. W. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10467 · Cited by 34 · see citing works
Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies
Capodivento, G., Visigalli, D., Garnero, M., Fancellu, R., Ferrara, M., Basit, A., Hamid, Z., Pastore, V. P., Garibaldi, S., Armirotti, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-08314-1 · Cited by 32 · see citing works
Targeted lipidomics and metabolomics evaluations of cortical neuronal stress in schizophrenia
Wood, P. L. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.08.003 · Cited by 30 · see citing works
Aquino, A., Alexandrino, G. L., Guest, P. C., Augusto, F., Gomes, A. F., Murgu, M., Steiner, J. H., & Martins‐de‐Souza, D. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00209 · Cited by 29 · see citing works
Self-citationMatam, Y., Ray, B. D., & Petrache, H. I. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.02.052 · Cited by 27 · see citing works
Phosphatidylserine reverses reserpine-induced amnesia
Alves, C. S. D., Andreatini, R., Cunha, C. D., Tufik, S., & Vital, M. A. B. F. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00607-5 · Cited by 26 · see citing works
Matsumoto, J., Nakanishi, H., Kunii, Y., Sugiura, Y., Yuki, D., Wada, A., Hino, M., Niwa, S., Kondo, T., Waki, M., et al. (2017) · Scientific Reports · doi:10.1038/srep45050 · Cited by 26 · see citing works
Chen, Y., Bang, S., McMullen, M. F., Kazi, H., Talbot, K., Ho, M.-X., Carlson, G. C., Arnold, S. E., Ong, W.-Y., & Kim, S. F. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9773-x · Cited by 25 · see citing works
Miller, J., Drost, D. J., Jensen, E., Manchanda, R., Northcott, S., Neufeld, R. W. J., Menon, R. S., Rajakumar, N., Pavlosky, W. F., Densmore, M., et al. (2012) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2011.06.017 · Cited by 23 · see citing works
Accumulation of N-Acylphosphatidylserines and N-Acylserines in the Frontal Cortex in Schizophrenia
Wood, P. L. (2015) · Neurotransmitter · doi:10.14800/nt.263 · Cited by 20 · see citing works
Beasley, C. L., Honer, W. G., Ramos‐Miguel, A., Vila‐Rodriguez, F., & Barr, A. M. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.05.033 · Cited by 18 · see citing works
Stefanidis, A., Watt, M. J., Cowley, M. A., & Oldfield, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.04.010 · Cited by 14 · see citing works
Effects of Risperidone on Lipid Profile
Khalili, H., Dashti‐Khavidaki, S., Okhovatpour, H., & Ghaeli, P. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1h669 · Cited by 10 · see citing works
Risperidone-Associated Increase in Triglyceride Levels
Weinbrenner, A., Peus, V., Inta, D., Englisch, S., & Zink, M. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08081169 · Cited by 9 · see citing works
Antipsychotic induced metabolic changes & treatment response: A prospective study
Sharma, E., Venkatasubramanian, G., Varambally, S. S., Sivakumar, P. T., Subbakrishna, D. K., & Gangadhar, B. N. (2014) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2014.05.001 · Cited by 8 · see citing works
Keshavan, M. S., Stanley, J. A., Montrose, D. M., Minshew, N. J., & Pettegrew, J. W. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001332 · Cited by 8 · see citing works
Profiling of Lipidomics Before and After Antipsychotic Treatment in First-Episode PsychosisPreprint
Leppik, L., Parksepp, M., Janno, S., et al. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3220097 · Cited by 2 · see citing works
Drs. Shekhar, McKinzie, and Felder Reply
Shekhar, A., McKinzie, D. L., & Felder, C. C. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08091352r1 · Cited by 1 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.
Cited by
Sorted by citations
Phosphatidylserine, inflammation, and central nervous system diseases
Ma, X., Li, X., Wang, W., Zhang, M., Yang, B., & Miao, Z. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.975176 · Cited by 91 · see citing works
Rognoni, C., Bertolani, A., & Jommi, C. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01000-1 · Cited by 94 · see citing works
LipidLynxX: a data transfer hub to support integration of large scale lipidomics datasetsPreprint
Ni, Z., & Fedorova, M. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.09.033894 · Cited by 50 · see citing works
Precision Medicine Approaches to Mental Health Care
Scala, J. J., Ganz, A. B., & Snyder, M. P. (2022) · Physiology · doi:10.1152/physiol.00013.2022 · Cited by 47 · see citing works
Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers
Zorkina, Y., Ushakova, V., Ochneva, A., Tsurina, A., Abramova, O., Savenkova, V., Goncharova, A., Alekseenko, I., Morozova, I., Riabinina, D., et al. (2024) · Metabolites · doi:10.3390/metabo14020080 · Cited by 36 · see citing works
Li, N., Yang, P., Tang, M., Liu, Y. H., Guo, W., Lang, B., Wang, J., Wu, H., Tang, H., Yu, Y. H., et al. (2022) · Schizophrenia · doi:10.1038/s41537-022-00214-2 · Cited by 34 · see citing works
Zhuo, C., Hou, W., Tian, H., Wang, L., & Li, R. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-01080-1 · Cited by 32 · see citing works
Phosphatidylserine: A comprehensive overview of synthesis, metabolism, and nutrition
Hussain, M., Khan, I. R., Chaudhary, M. N., Ali, K., Mushtaq, A., Jiang, B., Zheng, L., Pan, Y., Hu, J., & Zou, X. (2024) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2024.105422 · Cited by 25 · see citing works
The Role of GPR120 Receptor in Essential Fatty Acids Metabolism in Schizophrenia
Róg, J., Błażewicz, A., Juchnowicz, D., Ludwiczuk, A., Stelmach, E., Kozioł, M. M., Karakuła, M., Niziński, P., & Karakuła‐Juchnowicz, H. (2020) · Biomedicines · doi:10.3390/biomedicines8080243 · Cited by 22 · see citing works
The impact of quetiapine on the brain lipidome in a cuprizone-induced mouse model of schizophrenia
Zhou, C., Xue, S., Xue, F., Liu, L., Liu, J.-C., Ma, Q., Qin, J., Tan, Q.-R., Wang, H., & Peng, Z. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110707 · Cited by 22 · see citing works
Erythrocyte Membrane Fatty Acid Composition as a Potential Biomarker for Depression
Liu, T., Wang, L., Guo, J., Zhao, T., Tang, H., Dong, F., Wang, C., Chen, J., & Tang, M. (2023) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyad021 · Cited by 17 · see citing works
Couttas, T. A., Jieu, B., Rohleder, C., & Leweke, F. M. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.885904 · Cited by 17 · see citing works
Metabolomics, Lipidomics, and Antipsychotics: A Systematic Review
Burghardt, K. J., Kajy, M., Ward, K. M., & Burghardt, P. R. (2023) · Biomedicines · doi:10.3390/biomedicines11123295 · Cited by 16 · see citing works
Phulara, N. R., Rege, A., Bieberich, C. J., & Seneviratne, H. K. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00228 · Cited by 14 · see citing works
Identification of Plasma Biomarkers in Drug-Naïve Schizophrenia Using Targeted Metabolomics
Su, Q., Bi, F., Yang, S., Yan, H., Sun, X., Wang, J., Qiu, Y., Li, M., Li, S., & Li, J. (2023) · Psychiatry Investigation · doi:10.30773/pi.2023.0121 · Cited by 12 · see citing works
Shorter Chain Triglycerides Are Negatively Associated with Symptom Improvement in Schizophrenia
Tkachev, A., Stekolshchikova, E., Anikanov, N., Zozulya, S., Barkhatova, A., Klyushnik, T., & Petrova, D. (2021) · Biomolecules · doi:10.3390/biom11050720 · Cited by 11 · see citing works
“Antipsychotic treatment has previously been shown to affect both clinical lipid measurements, such as total triglycerides, and compounds at the level of lipid species [12,25,32,43,44].”
Guan, X., Xu, J., Xiu, M., Li, X., Liu, H., & Wu, F. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13895 · Cited by 10 · see citing works
Stolaki, E. V., Psatha, K., & Aivaliotis, M. (2025) · Metabolites · doi:10.3390/metabo15110750 · Cited by 9 · see citing works
Fu, Y., Wang, Q., Tang, Z., Liu, G., Guan, G., & Lyu, J. (2024) · Nutrients · doi:10.3390/nu16172859 · Cited by 6 · see citing works
Metabolic biomarkers of risperidone-induced weight gain in drug-naïve patients with schizophrenia
Qiu, Y., Dong, Y., Sun, W., Li, G., Li, M. J., Zhao, Y., Jiang, C., & Li, J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1144873 · Cited by 6 · see citing works
Zhou, M. (2024) · American Journal of Translational Research · doi:10.62347/idua6983 · Cited by 5 · see citing works
Identifying serum lipidomic signatures related to prognosis in first-episode schizophrenia
Luo, M., Zhang, S., Xue, J., Gao, T., Li, X., Zhai, Z., Lu, C., Dong, Y., Zhuo, K., Xiang, Q., et al. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06802-7 · Cited by 5 · see citing works
Jieu, B., Sykorova, E. B., Rohleder, C., Marcolini, E., Hoffmann, A., Koethe, D., Leweke, F. M., & Couttas, T. A. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116005 · Cited by 6 · see citing works
Fischer, L. E., Gottschalk, M. G., Reitz, L. U. G., Moussiopoulou, J., Koutsouleris, N., Yakimov, V., Boudriot, E., Seeburger, S., Jiang, T., Weiske, J., et al. (2025) · medRxiv · doi:10.1101/2025.05.14.25327624 · Cited by 4 · see citing works
Dai, S., Long, Y., Xiao, J., Wang, Y., Wang, X., Shao, P., Huang, M., Xu, Y., Liu, F., Tang, Y., et al. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104387 · Cited by 3 · see citing works
Known and Unexplored Post-Translational Modification Pathways in Schizophrenia
Smith, B. J., & Carregari, V. C. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-97182-3_6 · Cited by 3 · see citing works
Identification of serum metabolic traits of AIWG in first-episode schizophrenia patients
Zhang, S., Zhai, Z., Gao, T., Kuai, X., Li, X., Dong, Y., Lu, C., Zhuo, K., Xiang, Q., & Liu, D. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-06413-8 · Cited by 2 · see citing works
Villate, A., Olivares, M., Usobiaga, A., Unzueta‐Larrinaga, P., Barrena-Barbadillo, R., Callado, L. F., Etxebarría, N., & Urigüen, L. (2024) · Scientific Reports · doi:10.1038/s41598-024-83288-5 · Cited by 3 · see citing works
Synthetic Biology in Precision Medicine and Nanotechnology
Jayachandran, A., Ramakrishna, S., Shukla, R., Prithviraj, P., Kannourakis, G., & Poddar, A. (2026) · Springer eBooks · doi:10.1007/978-981-95-3957-4_37 · Cited by 1 · see citing works
Guo, Z., Zhang, Z. M., Li, L., Zhang, M., Huang, S., Li, Z., & Shang, D. (2025) · Current Neuropharmacology · doi:10.2174/1570159x23666241016090634 · Cited by 1 · see citing works
Pan, S.-Y., Song, X.-L., Lin, Z., Yu, Q., Zhang, Y., Tai, H., Luo, G., Wang, X., Zhu, P., Sun, N., et al. (2022) · Asian Pacific Journal of Tropical Biomedicine · doi:10.4103/2221-1691.335694
Multiomics Approaches in Psychiatric Disorders
Schulte, E. C., Kohshour, M. O., Tkachev, A., Khaitovich, P., & Schulze, T. G. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_30-1
Jiao, S., Li, N., Cao, T., Wang, L., Chen, H., Lin, C., & Cai, H. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111011
Hahnefeld, L., Hackel, J., Trautmann, S., Angioni, C., Schreiber, Y., Gurke, R., Thomas, D., Wicker, S., Geißlinger, G., & Tegeder, I. (2024) · Research Square · doi:10.21203/rs.3.rs-4408378/v1
Multiomics Approaches in Psychiatric Disorders
Schulte, E. C., Kohshour, M. O., Tkachev, A., Khaitovich, P., & Schulze, T. G. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_30
Blom, J. M. C., Ruggerini, C., Caroli, F., Ferreri, C., Masi, A., Rivi, V., Sarti, P., Rebecchi, M., & Arletti, C. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1608033
Weber, A., Papiol, S., Tkachev, A., Senner, F., Reich‐Erkelenz, D., Navarro‐Flores, A., Kohshour, M. O., Heilbronner, U., Heilbronner, M., Budde, M., et al. (2026) · medRxiv · doi:10.64898/2026.01.06.26343451
Plasma Lipid Alterations Track Multidimensional Psychosis Severity Across Diagnostic BoundariesPreprint
Thanabalasingam, A., Wiegand, A., Meijer, J., Dwyer, D., Schulte, E. C., & Study, T. P. (2026) · medRxiv · doi:10.64898/2026.02.24.26346956
- Authors
- de Almeida, V., Alexandrino, G. L., Aquino, A., Gomes, A. F., Murgu, M., Dobrowolny, H., Guest, P. C., Steiner, J., & Martins-de-Souza, D.
- Affiliations
- Universidade Estadual de Campinas (UNICAMP) (BR)
- Center for Behavioral Brain Sciences (DE)
- Venue
- Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 101
- Pages
- 109945
- ISSN
- 0278-5846 (ISSN-L)
- OpenAlex
- W3017362098
- Cited by
- 39
- References
- 68
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 11 · 2023: 5 · 2022: 7 · 2021: 2 · 2020: 5
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Progress in Neuro-Psychopharmacology and Biological Psychiatry (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed (publishedVersion)
- Funders
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
- Keywords
- schizophrenia, atypical antipsychotics, plasma lipidome, treatment response, risperidone, olanzapine, quetiapine, lipid biomarkers, ceramide, phospholipids, diacylglycerol, sphingomyelin, metabolic syndrome, lipid metabolism
- MeSH terms
- Lipidomics, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Schizophrenia, Antipsychotic Agents, Cohort Studies, Biomarkers, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
